CN111357858A - 一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 - Google Patents
一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 Download PDFInfo
- Publication number
- CN111357858A CN111357858A CN201910883764.2A CN201910883764A CN111357858A CN 111357858 A CN111357858 A CN 111357858A CN 201910883764 A CN201910883764 A CN 201910883764A CN 111357858 A CN111357858 A CN 111357858A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- earthworm protein
- tablet candy
- thrombus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 37
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 36
- 241000361919 Metaphire sieboldi Species 0.000 title claims abstract description 34
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 28
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 23
- 230000006870 function Effects 0.000 title claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002131 composite material Substances 0.000 title claims description 11
- 239000000843 powder Substances 0.000 claims abstract description 67
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 41
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 41
- 241000251468 Actinopterygii Species 0.000 claims abstract description 20
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 20
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 20
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 20
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 20
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 20
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 20
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 20
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 20
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 20
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 20
- 240000000249 Morus alba Species 0.000 claims abstract description 20
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 20
- 235000013557 nattō Nutrition 0.000 claims abstract description 19
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 240000008042 Zea mays Species 0.000 claims abstract description 17
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 17
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 17
- 235000005822 corn Nutrition 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 14
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 25
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims description 19
- 229920002774 Maltodextrin Polymers 0.000 claims description 19
- 239000005913 Maltodextrin Substances 0.000 claims description 17
- 229940035034 maltodextrin Drugs 0.000 claims description 17
- 239000001509 sodium citrate Substances 0.000 claims description 17
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
- 238000007873 sieving Methods 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 244000046146 Pueraria lobata Species 0.000 claims description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 239000000905 isomalt Substances 0.000 claims description 14
- 235000010439 isomalt Nutrition 0.000 claims description 14
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 229940026314 red yeast rice Drugs 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 5
- 244000182216 Mimusops elengi Species 0.000 claims description 5
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 30
- 235000018102 proteins Nutrition 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004185 liver Anatomy 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 108010064851 Plant Proteins Proteins 0.000 abstract description 2
- 235000021120 animal protein Nutrition 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 235000021118 plant-derived protein Nutrition 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 17
- 241001092040 Crataegus Species 0.000 description 14
- 235000013305 food Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical group CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229960001214 clofibrate Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- -1 flavonoid compound Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000243684 Lumbricus Species 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 2
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- KSZVHVUMUSIKTC-UHFFFAOYSA-N acetic acid;propan-2-one Chemical compound CC(C)=O.CC(O)=O KSZVHVUMUSIKTC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000435 effect on ear Effects 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 230000000615 effect on platelet disaggregation Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940012022 pentobarbital sodium 50 mg Drugs 0.000 description 1
- AALSLNDNKLOORP-UHFFFAOYSA-N perchloric acid sulfuric acid Chemical compound OS(O)(=O)=O.OCl(=O)(=O)=O AALSLNDNKLOORP-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种具有溶血栓和软化血管功能的多肽地龙蛋白压片糖果及其具体制备方法。本发明压片糖果主要由动物蛋白肽(地龙蛋白、海洋鱼低聚肽粉)和植物蛋白肽(大豆肽粉、玉米低聚肽粉)复配使用,使两种来源蛋白肽互相协同,进一步增强了复合低聚肽的软化血管和溶血栓活性。本发明配方还加入了桑葚、山楂、葛根、枸杞子、纳豆等具有补血、行气散瘀、滋补肝肾作用的药食同源中药,起到标本兼治的作用。另外,本发明的压片糖果营养丰富、口感良好、携带方便、易于消化吸收,卫生健康,口味好,符合现在市场的需求。
Description
技术领域
本发明涉及一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果 及其制备方法。
背景技术
血栓是血流在心血管系统血管内面剥落处或修补处的表面所形成的小块。 血栓形成是由于遗传和环境因素相互作用、相互影响的变化过程。临床常见的 血栓患者,最主要的特点有家族遗传性、反复发作性、症状严重性、以及发病 时间年轻化。现代人生活节奏快,饮食作息不规律,越来越多人出现血栓的状 况,血栓形成多在安静或睡眠中发病,部分病例有短暂性脑缺血发作(TIA)前 驱症状如肢体麻木无力等,突然出现偏侧上下肢麻木无力、口眼歪斜、言语不清 等症状,故软化血管与溶解血栓,保持机体健康是人们当前需要解决的难题。
随着人们生活水平的提高以及技术的发展,人们更加注重日常生活的保健。 食疗养生即通过饮食调理身体,是中国人的传统习惯,也是最直接的养生方式。 目前市场上软化血管功能的各类食品很多,但大多数存在食用与携带不方便、 吸收利用度不高和口感不好等问题。近年来营养性压片糖果因其具有携带方便, 口感好且有益于健康的优点而引起人们的关注,既可以充当食品,又含有功能 性组分,能起到调节身体、有助健康的作用,广受现代人们的喜爱。
发明内容
基于此,本发明在于克服现有技术的缺陷,提供一种具有溶血栓和软化血 管功能的复合多肽地龙蛋白压片糖果及其制备方法。
为实现上述目的,本发明可以通过以下技术方案予以实现:
一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,由下列重 量份的原料制成:异麦芽酮糖醇20-30份、麦芽糊精20-30份、地龙蛋白10-20 份、大豆肽粉15-25份、海洋鱼低聚肽粉10-20份、玉米低聚肽粉10-20份、 桑葚6-12份、山楂6-12份、葛根3-6份、枸杞子6-12份、纳豆3-6份、食品 添加剂11-23份。
优选的,所述食品添加剂按照质量份包括:微晶纤维素3-7份、维生素C 1-2 份、红曲米1-2份、柠檬酸钠3-6份、硬脂酸镁3-6份。
优选的,一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果, 由下列重量份的原料制成:异麦芽酮糖醇20份、麦芽糊精30份、地龙蛋白10 份、大豆肽粉25份、海洋鱼低聚肽粉10份、玉米低聚肽粉20份、桑葚6份、 山楂12份、葛根3份、枸杞子12份、纳豆3份、微晶纤维素7份、维生素C 1 份、红曲米2份、柠檬酸钠3份、硬脂酸镁6份。
优选的,一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果, 由下列重量份的原料制成:异麦芽酮糖醇25份、麦芽糊精25份、地龙蛋白15 份、大豆肽粉20份、海洋鱼低聚肽粉15份、玉米低聚肽粉15份、桑葚10份、 山楂9份、葛根5份、枸杞子8份、纳豆4份、微晶纤维素5份、维生素C 1.5 份、红曲米1.5份、柠檬酸钠4份、硬脂酸镁5份。
优选的,一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果, 由下列重量份的原料制成:异麦芽酮糖醇30份、麦芽糊精20份、地龙蛋白20 份、大豆肽粉15份、海洋鱼低聚肽粉20份、玉米低聚肽粉10份、桑葚12份、 山楂6份、葛根6份、枸杞子6份、纳豆6份、微晶纤维素3份、维生素C 2 份、红曲米1份、柠檬酸钠6份、硬脂酸镁3份。
一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果的制备方 法,包括以下步骤:
(1)按照原料重量比例称取,净选;
(2)分别将异麦芽糖酮糖醇、麦芽糊精、地龙蛋白、大豆肽粉、海洋鱼低 聚肽粉、玉米低聚肽粉、桑葚、山楂、葛根、枸杞子、纳豆、微晶纤维素、维 生素C、红曲米、柠檬酸钠进行干燥,粉碎,过80目筛,备用;
(3)将步骤(2)所得细粉于高速混合机中混合10-20min,往混合均匀的 混合粉内加入70-90%食用酒精,进行湿法制粒,过20目筛,得到湿颗粒;
(4)将颗粒置入沸腾干燥机中,干燥温度为50-60℃,干燥时间40-50min, 至颗粒水分<5%时,取出颗粒冷却至室温,过20目筛整粒;
(5)将整粒后的颗粒加入硬脂酸镁,混合20分钟,压片,即得成品。
异麦芽酮糖醇具有如蔗糖一般的纯正味道,无不良后味及异味,可与强力 甜味剂发生协同增效作用并掩盖后者的不良后味及异味,低吸湿性、高稳定性, 低能量、非龋齿性等,所以它更是一种完美的糖替代品。目前异麦芽酮糖醇已 被广泛应用于各类食品的生产:硬糖软糖、口香糖、巧克力、果冻、清凉饮料、 冰淇淋、烘烤制品和压片等方面。异麦芽酮糖醇具备众多的优良特性,所以它 适合于用普通的生产设备生产的产品。
麦芽糊精是淀粉的水解产物。它介于淀粉和淀粉糖之间,是一种价格低廉、 口感滑腻、没有任何味道的营养性多糖。麦芽糊精一般为多种DE值(葡萄糖当 量值)的混合物。它可以是白色粉末,也可以是浓缩液体。流动性良好,无异 味,几乎没有甜度。溶解性能良好,有适度的粘度。吸湿性低,不易结团。有 较好的载体作用,是各种甜味剂、香味剂、填充剂等的优良载体。有很好的乳 化作用和增稠效果。有促进产品成型和良好地抑制产品组织结构的作用。成膜 性能好,既能防止产品变形又能改善产品外观。极易被人体吸收,特别适宜作 病人和婴幼儿童食品的基础原料。对食品饮料的泡沫有良好的稳定效果。具有 甜度低,无异味,易消化,低热,溶解性好,发酵性小,填充效果好,不易吸 潮,增稠性强,载体性好,稳定性好,难以变质的特性。麦芽糊精含有大量的 多糖类,另外还含有钙、铁等对人体有益的微量元素及矿物质,并能促进人体 正常的物质代谢。
地龙,性味寒、咸,归肾、肺、肝经。主要功效为平肝息风、通络、利尿、 清热止痉、平喘等。主治热病发热狂躁、肝阳头痛、风湿痹痛、小便不通、惊 痈抽搐、中风偏瘫、肺热喘咳等症。地龙中的蛋白质化合物即地龙蛋白对人体 内的凝血系统和纤溶系统具有广泛的影响,既可明显降低大鼠血小板黏附率, 延长体内血栓形成和溶解体内血栓,又能增加脑血流量,减少脑血管阻力,改 善微循环,减少三高对人体的危害。
大豆肽粉易被人体吸收,它可不经胃肠消化,直接进入小肠被吸收,而且 不受身体状况所影响。豆肽粉含有多种生物活性肽,具有多种生理活性,包括 抗氧化、降血压、降低胆固醇、降血脂、抗疲劳、增强免疫等。作为一种新型 多功能营养配料,大豆肽粉可广泛地用于保健食品、婴幼儿食品、运动食品、 发酵制品及临床营养制剂等。
海洋鱼低聚肽粉可以降低疲劳后乳酸和尿素氮含量,提高了肝糖原含量和 超氧化物歧化酶、过氧化氢酶及谷胱甘肽过氧化物酶活性,说明低值海洋鱼低 聚肽能提高运动耐力,缓解疲劳。
玉米低聚肽粉是以玉米蛋白粉为原料,经调浆、蛋白酶酶解、分离、过滤、 喷雾干燥等工艺生产而成的。其是一种新资源产品,可应用于降血压、醒酒护 肝、增强免疫。
桑葚果实中含有丰富的活性蛋白、维生素、氨基酸、胡萝卜素、矿物质、 白藜芦醇、花青素等成份,能显著提高人体免疫力,具有延缓衰老、美容养颜 的功效。现代药理研究表明桑椹多糖具有降血脂、改善血液黏聚状态及抗脂质 过氧化作用。
山楂是中国特有的药果兼用树种,具有降血脂、血压、强心、抗心律不齐 等作用,同时也是健脾开胃、消食化滞、活血化痰的良药,对胸膈脾满、疝气、 血淤、闭经等症有很好的疗效。山楂内的黄酮类化合物牡荆素,是一种抗癌作 用较强的药物,其提取物对抑制体内癌细胞生长、增殖和浸润转移均有一定的 作用。
葛根的性味甘、辛,凉。有解肌退热、透疹、生津止渴、升阳止泻之功。 常用于表证发热,项背强痛,麻疹不透,热病口渴,阴虚消渴,热泻热痢,脾 虚泄泻。研究表明,葛根中的葛根素不仅可降低血细胞聚集率、黏附率、血液 粘滞度以及抑制血栓的形成,而且对高黏度凝血症也具有一定的预防和治疗作 用。葛根素通过改变血流速度及血管形态来改善微循环,达到治疗突发性耳聋 和改善视网膜血液供应的作用。另外,葛根素可通过抑制内皮素来提高降钙素 基因的生成,达到改善脑部血循环的作用。
枸杞子的功效为滋肾、润肺、补肝、明目。治肝肾阴亏、腰膝酸软、头晕、 目眩、目昏多泪、虚劳咳嗽、消渴、遗精。动物试验显示,枸杞子能提高正常 小鼠的造血功能,同时,对环磷酰胺导致白细胞受抑小鼠的造血功能也有提升 效果。
纳豆具有黏性,气味较臭,味道微甜,不仅保有黄豆的营养价值、富含维 生素K2、提高蛋白质的消化吸收率,发酵过程产生多种生理活性物质,具有溶 解体内纤维蛋白及其他调节生理机能的保健作用,富含多种营养素,可以预防 便秘、腹泻等肠道疾病,提高骨密度,预防骨质疏松,还可双向调节血压,溶 解陈旧血栓斑块,调节血脂,能消除疲劳,综合提高人体免疫力。
本发明压片糖果主要由动物蛋白肽(地龙蛋白、海洋鱼低聚肽粉)和植物 蛋白肽(大豆肽粉、玉米低聚肽粉)复配使用,使两种来源蛋白肽互相协同, 进一步增强了复合低聚肽的软化血管和溶血栓活性。
本发明配方还加入了桑葚、山楂、葛根、枸杞子、纳豆等具有补血、行气 散瘀、滋补肝肾作用的药食同源中药,起到标本兼治的作用。
本发明的压片糖果营养丰富、口感良好、携带方便、易于消化吸收,卫生 健康,口味好,符合现在市场的需求。
具体实施方式
为了使本发明专利的目的、技术方案及优点更加清楚明白,以下结合实施 例,对本发明专利进行进一步详细说明。应当理解,此处所描述的具体实施例 仅仅用以解释本发明专利,并不用于限定本发明专利。
实施例1
配方:
异麦芽酮糖醇20,麦芽糊精30,地龙蛋白10,大豆肽粉25,海洋鱼低聚 肽粉10,玉米低聚肽粉20,桑葚6,山楂12,葛根3,枸杞子12,纳豆3,食 品添加剂(微晶纤维素7、维生素C 1、红曲米2、柠檬酸钠3、硬脂酸镁6)。
制备方法:
(1)按照原料重量比例称取,净选;
(2)分别将异麦芽糖酮糖醇、麦芽糊精、地龙蛋白、大豆肽粉、海洋鱼低 聚肽粉、玉米
低聚肽粉、桑葚、山楂、葛根、枸杞子、纳豆、微晶纤维素、维生素C、红 曲米、柠檬酸钠进行干燥,粉碎,过80目筛,备用;
(3)将步骤(2)所得细粉于高速混合机中混合10min,往混合均匀的混合 粉内加入70%
食用酒精,进行湿法制粒,过20目筛,得到湿颗粒;
(4)将颗粒置入沸腾干燥机中,干燥温度为50℃,干燥时间40min,至颗 粒水分3%时,
取出颗粒冷却至室温,过20目筛整粒;
(5)将整粒后的颗粒加入硬脂酸镁,混合20分钟,压片,即得成品。
实施例2
配方:
异麦芽酮糖醇25,麦芽糊精25,地龙蛋白15,大豆肽粉20,海洋鱼低聚 肽粉15,玉米低聚肽粉15,桑葚10,山楂9,葛根5,枸杞子8,纳豆4,食品 添加剂(微晶纤维素5、维生素C1.5、红曲米1.5、柠檬酸钠4、硬脂酸镁5)。
制备方法:
(1)按照原料重量比例称取,净选;
(2)分别将异麦芽糖酮糖醇、麦芽糊精、地龙蛋白、大豆肽粉、海洋鱼低 聚肽粉、玉米
低聚肽粉、桑葚、山楂、葛根、枸杞子、纳豆、微晶纤维素、维生素C、红 曲米、柠檬酸钠进行干燥,粉碎,过80目筛,备用;
(3)将步骤(2)所得细粉于高速混合机中混合15min,往混合均匀的混合 粉内加入80%
食用酒精,进行湿法制粒,过20目筛,得到湿颗粒;
(4)将颗粒置入沸腾干燥机中,干燥温度为55℃,干燥时间45min,至颗 粒水分3.5%时,
取出颗粒冷却至室温,过20目筛整粒;
(5)将整粒后的颗粒加入硬脂酸镁,混合20分钟,压片,即得成品。
实施例3
配方:
异麦芽酮糖醇30,麦芽糊精20,地龙蛋白20,大豆肽粉15,海洋鱼低聚 肽粉20,玉米低聚肽粉10,桑葚12,山楂6,葛根6,枸杞子6,纳豆6,食品 添加剂(微晶纤维素3、维生素C2、红曲米1、柠檬酸钠6、硬脂酸镁3)。
制备方法:
(1)按照原料重量比例称取,净选;
(2)分别将异麦芽糖酮糖醇、麦芽糊精、地龙蛋白、大豆肽粉、海洋鱼低 聚肽粉、玉米
低聚肽粉、桑葚、山楂、葛根、枸杞子、纳豆、微晶纤维素、维生素C、红 曲米、柠檬酸钠进行干燥,粉碎,过80目筛,备用;
(3)将步骤(2)所得细粉于高速混合机中混合20min,往混合均匀的混合 粉内加入90%
食用酒精,进行湿法制粒,过20目筛,得到湿颗粒;
(4)将颗粒置入沸腾干燥机中,干燥温度为60℃,干燥时间50min,至颗 粒水分4%时,
取出颗粒冷却至室温,过20目筛整粒;
(5)将整粒后的颗粒加入硬脂酸镁,混合20分钟,压片,即得成品。
为了证实本发明具有溶血栓和软化血管的功能,用按实施例2方法制成的 压片糖果,进行了一下动物实验研究:
1实验材料
1.1实验药物
多肽地龙蛋白压片糖果及原粉,按实施例2方法制备。其他药物均外购。
1.2实验动物:
大鼠、小鼠购自广东省医学实验动物中心。
全部实验均设对照组,给予等容量水或生理盐水。
1.3实验仪器
2实验方法与结果
2.1对实验性高脂血症大鼠的影响
选用体重180g左右雄性大鼠,每日喂饲高脂饲料(由鲜蛋黄、猪油、胆盐、 甲基硫氧嘧啶及普通饲料按一定比例配成),每日每只喂食量约20g。一周后, 与喂饲普通饲料大鼠同时测定血清胆固醇和甘油三脂含量,结果见表1。确定高 脂血症模型形成后供实验用。
高脂血症大鼠分四组(高脂对照组、治疗Ⅰ组、治疗Ⅱ组、安妥明组)继 续喂饲高脂饲料,另设正常对照组。治疗Ⅰ、Ⅱ组分别灌胃给予压片糖果5.0g 和10.0g/kg,每日二次。安妥明组灌胃给予安妥明200mg/kg,每日二次。高脂 及正常对照组分别给予等容量水。连续给药十天,末次给药后2h乙醚麻醉,腹 主动脉取血,分离血清,测定血清胆固醇(乙醇提取,高铁-硫酸显色法)、甘 油三脂(异丙醇提取,乙酸丙酮显色法)、β脂蛋白(肝素-锰比浊法)、磷脂 (醇醚混合液提取,硫酸过氯酸消化,抗坏血酸为还原剂法),结果见表2。
解剖动物,观察主动脉及各脏器变化,肝重量与体重之比值以及药物对血 清谷丙转氨酶(定量法测定)的影响。
*p<0.05,**p<0.01,***p<0.001均为与高脂对照组比较结果
由表2可见,压片糖果10.0g×2/日,能明显降低高脂血症大鼠血清胆固醇、 甘油三脂、β脂蛋白及磷脂的含量,与高脂对照组相比有非常显著的差异 (p<0.001),与降血脂药安妥明200mg×2/日相比,作用很相近。
喂饲高脂饲料造型一周期间,各组体重增长无明显差别,给药组比高脂对 照组增长缓慢。解剖动物肉眼观察,主动脉及其他器官无斑块形成,对肝脏重 量也无明显影响。
压片糖果5g×2/日、10g×2/日灌胃给药均能明显降低大鼠高脂血症,安妥 明200mg/kg作用不明显。
2.2对大鼠血小板聚集和解聚的影响
选用体重200g左右雄性大鼠,随机分组。灌胃给予阿斯匹林300mg/kg,给 药两次(间隔15h)4h后测定。压片糖果10g/kg,每日两次,连续三天,末次 给药后2h进行侧定。腹注戊巴比妥钠麻醉,主动脉取血,3.8%枸椽酸钠抗凝。 制备富血小板血浆(PPP)及少血小板血浆(PRP),用PPP将PRP中血小板数 调整到75万/mm3,以ADP为诱导剂(终浓度1μg/mLPRP),在BS631型血小板聚 集仪上测定血小板聚集性及解聚速度,与对照组比较,统计处理。
结果软化血管片10g/kg灌胃给药对大鼠血小板聚集反应有明显的抑制作用 (p<0.001),对聚集血小板解聚也有明显促进作用(p<0.01)。
2.3对大鼠实验性血检形成的影响
选用300g左右雄性大鼠,随机分组。腹注戊巴比妥钠50mg/kg麻醉,气管 内插聚乙烯管以消除分泌物,分离右颈总动脉和左颈外静脉,取二段聚乙烯管,, 中间连内放5cm手术线的硅胶管,管内充满肝素生理盐水,静注肝素5μ/kg, 将管两端分别插入动静脉内。开放血流15min后,取出手术线称重,总重量减 去线重为血栓湿重,求出抑制率,并与尿激酶比较。
结果,压片糖果4g和6g/kg静脉给药,10g/kg灌胃给药对大鼠实验性血栓 形成均有非常显著的抑制作用。
2.4对二甲笨所致小鼠耳部炎症的影响
体重20g左右雄性小鼠,随机分四组,每组10只。按表3所示剂量腹腔注 射给药。1h后于每鼠左耳滴二甲苯0.04mL致炎。20min后齐耳根剪下小鼠两耳, 用8mm角膜环钻在同一部位取下两耳园片,迅迅称重,其差值反映肿胀程度, 结果见表3。
表3压片糖果对二甲笨所致小限耳部炎症的影响
*p<0.05,**p<0.01
表3所示,压片糖果5g/kg腹腔注射对二甲苯所致小鼠耳部炎症有非常明 显的抑制作用。
3实验结论
实验结果表明,压片糖果能明显降低高脂血症大鼠血清胆固酶、甘油三酷、 β脂蛋白及磷脂的含量,以10g×2/日灌胃给药即与降血脂药安妥明0.2g×2/ 日相似。已知安妥明能降低甘油三醋和极低密度脂蛋白(VLDL),但对低密度 脂蛋白(LDL)的作用很小,是Ⅰ和Ⅱ型高脂血症的首选药。该药副反应大多限 于胃肠道,恶心、腹部不适是最常见的副反应,偶也有严重的副反应。压片糖 果则对多种脂类(胆固酶、甘油三醋β脂蛋白、磷脂)均能降低其血浆水平, 可以推测应用范围将比安妥明更大,且对机体无明显副作用,从这方面看,优于安妥明。该压片糖果对大鼠血小板聚集反应有显著抑制作用,亦能促进解聚。 此外口服给药对大鼠实验性血栓形成有非常显著抑制作用并具有抗炎作用。
以上所述实施例仅表达了本发明的一种实施方式,只是在于说明而不是限 制本发明。对于本领域的普通技术人员来说,在不脱离本发明构思的前提下, 还可以做出若干变形和改进。因此,本发明的保护范围应以所附权利要求为准。
Claims (6)
1.一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,其特征在于由下列重量份的原料制成:异麦芽酮糖醇20-30份、麦芽糊精20-30份、地龙蛋白10-20份、大豆肽粉15-25份、海洋鱼低聚肽粉10-20份、玉米低聚肽粉10-20份、桑葚6-12份、山楂6-12份、葛根3-6份、枸杞子6-12份、纳豆3-6份、食品添加剂11-23份。
2.根据权利要求1所述的一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,其特征在于所述食品添加剂按照质量份包括:微晶纤维素3-7份、维生素C1-2份、红曲米1-2份、柠檬酸钠3-6份、硬脂酸镁3-6份。
3.根据权利要求2所述的一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,其特征在于由下列重量份的原料制成:异麦芽酮糖醇20份、麦芽糊精30份、地龙蛋白10份、大豆肽粉25份、海洋鱼低聚肽粉10份、玉米低聚肽粉20份、桑葚6份、山楂12份、葛根3份、枸杞子12份、纳豆3份、微晶纤维素7份、维生素C1份、红曲米2份、柠檬酸钠3份、硬脂酸镁6份。
4.根据权利要求2所述的一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,其特征在于由下列重量份的原料制成:异麦芽酮糖醇25份、麦芽糊精25份、地龙蛋白15份、大豆肽粉20份、海洋鱼低聚肽粉15份、玉米低聚肽粉15份、桑葚10份、山楂9份、葛根5份、枸杞子8份、纳豆4份、微晶纤维素5份、维生素C1.5份、红曲米1.5份、柠檬酸钠4份、硬脂酸镁5份。
5.根据权利要求2所述的一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果,其特征在于由下列重量份的原料制成:异麦芽酮糖醇30份、麦芽糊精20份、地龙蛋白20份、大豆肽粉15份、海洋鱼低聚肽粉20份、玉米低聚肽粉10份、桑葚12份、山楂6份、葛根6份、枸杞子6份、纳豆6份、微晶纤维素3份、维生素C 2份、红曲米1份、柠檬酸钠6份、硬脂酸镁3份。
6.一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果的制备方法,其特征在于包括以下步骤:
(1)按照原料重量比例称取,净选;
(2)分别将异麦芽糖酮糖醇、麦芽糊精、地龙蛋白、大豆肽粉、海洋鱼低聚肽粉、玉米低聚肽粉、桑葚、山楂、葛根、枸杞子、纳豆、微晶纤维素、维生素C、红曲米、柠檬酸钠进行干燥,粉碎,过80目筛,备用;
(3)将步骤(2)所得细粉于高速混合机中混合10-20min,往混合均匀的混合粉内加入70-90%食用酒精,进行湿法制粒,过20目筛,得到湿颗粒;
(4)将颗粒置入沸腾干燥机中,干燥温度为50-60℃,干燥时间40-50min,至颗粒水分<5%时,取出颗粒冷却至室温,过20目筛整粒;
(5)将整粒后的颗粒加入硬脂酸镁,混合20分钟,压片,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910883764.2A CN111357858A (zh) | 2019-09-18 | 2019-09-18 | 一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910883764.2A CN111357858A (zh) | 2019-09-18 | 2019-09-18 | 一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111357858A true CN111357858A (zh) | 2020-07-03 |
Family
ID=71198497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910883764.2A Pending CN111357858A (zh) | 2019-09-18 | 2019-09-18 | 一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111357858A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112603994A (zh) * | 2020-12-24 | 2021-04-06 | 陕西中鸿科瑞再生医学研究院有限公司 | 日常防治微血栓的组合物及用途 |
CN113057336A (zh) * | 2021-04-15 | 2021-07-02 | 熊夜 | 一种辅助降三高的营养组合物及其制备方法 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
CN114642236A (zh) * | 2022-03-23 | 2022-06-21 | 广州高人汇生物科技有限公司 | 一种可以辅助降血压的小球藻纳豆压片糖果 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104938740A (zh) * | 2014-03-28 | 2015-09-30 | 湖南九芝堂医药科技有限公司 | 一种海洋鱼低聚肽粉压片糖果及其制备方法 |
CN106474219A (zh) * | 2016-11-11 | 2017-03-08 | 天津蚓福生物科技开发有限公司 | 降血脂压片糖果 |
CN106858586A (zh) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | 一种防治心脑血管疾病的地龙蛋白纳豆人参复合蛋白产品 |
-
2019
- 2019-09-18 CN CN201910883764.2A patent/CN111357858A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104938740A (zh) * | 2014-03-28 | 2015-09-30 | 湖南九芝堂医药科技有限公司 | 一种海洋鱼低聚肽粉压片糖果及其制备方法 |
CN106474219A (zh) * | 2016-11-11 | 2017-03-08 | 天津蚓福生物科技开发有限公司 | 降血脂压片糖果 |
CN106858586A (zh) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | 一种防治心脑血管疾病的地龙蛋白纳豆人参复合蛋白产品 |
Non-Patent Citations (3)
Title |
---|
姜锡瑞: "《生物发酵产业技术》", 31 May 2016, 中国轻工业出版社 * |
胡家才等: "《肿瘤患者的中医饮食疗法》", 31 December 2018, 武汉大学出版社 * |
胡维勤: "《食物与药物使用宜忌速查图解》", 31 January 2018, 江西科学技术出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112603994A (zh) * | 2020-12-24 | 2021-04-06 | 陕西中鸿科瑞再生医学研究院有限公司 | 日常防治微血栓的组合物及用途 |
CN112603994B (zh) * | 2020-12-24 | 2024-03-12 | 陕西中鸿科瑞再生医学研究院有限公司 | 日常防治微血栓的组合物及用途 |
CN113057336A (zh) * | 2021-04-15 | 2021-07-02 | 熊夜 | 一种辅助降三高的营养组合物及其制备方法 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
CN114642236A (zh) * | 2022-03-23 | 2022-06-21 | 广州高人汇生物科技有限公司 | 一种可以辅助降血压的小球藻纳豆压片糖果 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111357858A (zh) | 一种具有溶血栓和软化血管功能的复合多肽地龙蛋白压片糖果及其制备方法 | |
CN102511869B (zh) | 红枣生姜浓浆 | |
CN102511867B (zh) | 红枣阿胶枸杞浓浆及其生产工艺 | |
JP2006238730A (ja) | 肝機能強化性健康食品 | |
CN114128813A (zh) | 一种用于解酒护肝后生元饮品及其制备方法 | |
CN104839698A (zh) | 心血管疾病非全营养配方食品 | |
CN103609701A (zh) | 一种适合脂肪肝患者饮用的酸奶及加工工艺 | |
CN113855766A (zh) | 一种可调理血压的银杏蛹虫草冲剂 | |
CN105341300A (zh) | 一种适宜儿童食用的保健糖果 | |
CN103263054B (zh) | 一种降血压功能性饮品 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
KR101930433B1 (ko) | 밀웜을 함유한 양갱의 제조방법 및 이에 따라 제조된 밀웜 양갱 | |
CN112167639A (zh) | 一种双向调节晨起肠道液体平衡的组合物、制备方法及其用途 | |
CN109481578A (zh) | 一种复合代用茶及其制作方法 | |
CN105505703B (zh) | 娃娃鱼养生酒制作方法 | |
CN113068784A (zh) | 一种缓解身体疼痛的sod饮液及其制备方法 | |
CN102511882A (zh) | 一种有助于改善生长发育的红枣浓浆 | |
CN106421519A (zh) | 一种保健药酒 | |
CN102511879B (zh) | 红枣龟苓浓浆 | |
CN102511860B (zh) | 一种添加植物甾醇适合孕妇食用的红枣浓浆 | |
CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 | |
KR20210041387A (ko) | 갈화 추출물 및 차전자피 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
CN108685101A (zh) | 林蛙肽菊粉 | |
CN110507770A (zh) | 一种双叶薏枣清降代用茶 | |
CN110547409A (zh) | 一种具有健脾益胃、美容养颜功能的皮冻及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |
|
RJ01 | Rejection of invention patent application after publication |